Red Light Holland Engages Kala Bio's Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug Candidate

Stock Information for KALA BIO Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About KALA BIO Inc.

Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates
KALA BIO Settles Approximately $10.6 million of Debt
KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
KALA BIO Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint
KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference
KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.